CD274 and hepatocellular carcinoma: Atezolizumab can reactivate T cell cytotoxicity by blocking PD-L1 from binding to PD-1 or A7-1 receptors [43], and the single-agent OR rate was 17% in patients with advanced HCC in a phase Ib study [44].